Top 10 Companies in the (S)-N-ALPHA-T-BUTYLOXYCARBONYL-PYROGLUTAMIC ACID T-BUTYL ESTER (CAS 91229-91-3) Market (2026): Market Leaders Powering Global Peptide Synthesis

MARKET INSIGHTS

Global (S)-N-Alpha-T-Butyloxycarbonyl-Pyroglutamic Acid T-Butyl Ester (CAS 91229-91-3) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-N-Alpha-T-Butyloxycarbonyl-Pyroglutamic Acid T-Butyl Ester (CAS 91229-91-3) is a protected amino acid derivative widely used as a key building block in peptide synthesis and pharmaceutical research. The compound features a Boc (tert-butyloxycarbonyl) protecting group on the alpha-amino function and a tert-butyl ester on the carboxyl terminus, making it particularly valuable in solid-phase and solution-phase peptide chemistry where orthogonal protection strategies are required.

The market is witnessing steady growth driven by rising demand for complex peptide-based therapeutics and the expanding pipeline of peptide drugs globally. Furthermore, increasing investment in pharmaceutical R&D and the growing adoption of advanced peptide synthesis technologies are reinforcing market momentum. Key suppliers of specialty protected amino acid derivatives, including Bachem AG, Iris Biotech GmbH, and Sigma-Aldrich (Merck KGaA), maintain prominent positions in this specialized fine chemicals segment.

(S)-N-ALPHA-T-BUTYLOXYCARBONYL-PYROGLUTAMIC ACID T-BUTYL ESTER (CAS 91229-91-3) Market – View in Detailed Research Report

Top 10 Companies in the (S)-N-ALPHA-T-BUTYLOXYCARBONYL-PYROGLUTAMIC ACID T-BUTYL ESTER (CAS 91229-91-3) Market (2026)

🔟 1. Bachem AG

Headquarters: Balgach, Switzerland
Key Offering: High‑purity Boc‑protected pyroglutamic acid derivatives for peptide synthesis

Bachem AG is a leading fine‑chemical manufacturer with a strong portfolio of protected amino acids. Its state‑of‑the‑art synthesis platform delivers >98% enantiomeric excess and stringent GMP compliance, ensuring reliable supply for pharmaceutical and biopharmaceutical R&D.

Sustainability & Growth Initiatives:

• Investment in green chemistry and reduced‑energy synthesis routes
• Expansion of cGMP facilities to support large‑scale peptide drug development
• Digital supply chain platform for real‑time inventory and traceability

🧩 9. Biosynth

Headquarters: Brugg, Switzerland
Key Offering: Custom synthesis of Boc‑protected amino acids and specialty intermediates

Biosynth specializes in bespoke synthesis for academic and industrial clients, providing rapid turnaround and analytical support for complex peptide building blocks.

Sustainability & Growth Initiatives:

• ISO 14001 environmental management system implementation
• Collaboration with academic partners for process optimization
• Adoption of continuous flow synthesis to reduce waste

🔹 8. Iris Biotech GmbH

Headquarters: Munich, Germany
Key Offering: Specialty protected amino acids for peptide chemistry and drug discovery

Iris Biotech offers a portfolio of high‑purity Boc‑protected pyroglutamic acid derivatives with rapid scale‑up capabilities, supporting early‑stage peptide therapeutics.

Sustainability & Growth Initiatives:

• Carbon‑neutral production targets by 2035
• Use of renewable feedstocks in synthesis routes
• Transparent reporting of environmental metrics

🔸 7. Advanced ChemTech

Headquarters: San Diego, California, USA
Key Offering: Custom synthesis of chiral amino acids and protected intermediates

Advanced ChemTech combines rigorous chiral analytics with scalable production, enabling high‑purity Boc‑protected building blocks for complex peptide assembly.

Sustainability & Growth Initiatives:

• Implementation of waste‑reduction protocols in synthesis labs
• Partnerships with universities for process development
• Investment in automated synthesis equipment for higher throughput

🔧 6. Chem‑Impex International, Inc.

Headquarters: Cleveland, Ohio, USA
Key Offering: Fine‑chemical synthesis of Boc‑protected amino acids and specialty intermediates

Chem‑Impex delivers high‑purity Boc‑protected pyroglutamic acid derivatives with robust quality control and rapid delivery for R&D laboratories worldwide.

Sustainability & Growth Initiatives:

• Green chemistry initiatives to lower solvent usage
• Digital traceability of raw materials and product batches
• Continuous improvement of chiral resolution techniques

🔬 5. PolyPeptide Group

Headquarters: Gothenburg, Sweden
Key Offering: Custom synthesis of protected amino acids for peptide therapeutics

PolyPeptide Group specializes in scalable production of Boc‑protected pyroglutamic acid derivatives, supporting both research and early‑stage development.

Sustainability & Growth Initiatives:

• ISO 50001 energy management system
• Use of renewable electricity in manufacturing facilities
• Research into alternative protecting groups to reduce waste

🧪 4. Tokyo Chemical Industry Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: High‑purity Boc‑protected amino acids for peptide synthesis

Tokyo Chemical Industry leverages advanced chiral synthesis platforms to deliver Boc‑protected pyroglutamic acid derivatives with consistent enantiomeric excess for pharmaceutical applications.

Sustainability & Growth Initiatives:

• Zero‑waste manufacturing targets
• Investment in renewable energy sources
• Collaboration with biotech firms for process optimization

⚙️ 3. Gleison Pharmaceuticals Pvt. Ltd.

Headquarters: Mumbai, India
Key Offering: Custom synthesis of Boc‑protected amino acids and specialty intermediates

Gleison focuses on scalable production of high‑purity Boc‑protected pyroglutamic acid derivatives for the Indian and global biopharmaceutical markets.

Sustainability & Growth Initiatives:

• Adoption of green chemistry protocols to reduce hazardous waste
• ISO 14001 environmental management
• Partnerships with research institutions for process development

🔍 2. Finetech Industry Limited

Headquarters: Shanghai, China
Key Offering: Fine‑chemical synthesis of Boc‑protected pyroglutamic acid derivatives

Finetech Industry offers rapid scale‑up and high‑purity Boc‑protected building blocks, supporting both academic research and industrial peptide production.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recovery systems
• ISO 9001 quality management system
• Investment in renewable energy for manufacturing plants

🛠️ 1. ChemPep Inc.

Headquarters: Los Angeles, California, USA
Key Offering: Custom synthesis of Boc‑protected amino acids for peptide chemistry

ChemPep Inc. delivers high‑purity Boc‑protected pyroglutamic acid derivatives with rigorous analytical support and flexible order sizes for R&D and industrial clients.

Sustainability & Growth Initiatives:

• Green chemistry initiatives to reduce solvent usage
• Digital supply chain and real‑time tracking of product batches
• Continuous improvement of chiral resolution techniques

Download FREE Sample Report: (S)-N-ALPHA-T-BUTYLOXYCARBONYL-PYROGLUTAMIC ACID T-BUTYL ESTER (CAS 91229-91-3) Market – View in Detailed Research Report

Get Full Report Here: (S)-N-ALPHA-T-BUTYLOXYCARBONYL-PYROGLUTAMIC ACID T-BUTYL ESTER (CAS 91229-91-3) Market – View in Detailed Research Report

🌍 Outlook: The Future of (S)-N-ALPHA-T-BUTYLOXYCARBONYL-PYROGLUTAMIC ACID T-BUTYL ESTER Market

The global peptide therapeutics market is projected to continue expanding, driven by unmet medical needs in oncology, metabolic disorders, and CNS diseases. As the number of peptide drug approvals rises, demand for high‑purity, stereochemically defined building blocks such as (S)-N‑Alpha‑T‑Butyloxycarbonyl‑Pyroglutamic Acid T‑Butyl Ester will increase. Companies that can deliver consistent chiral purity, robust GMP compliance, and rapid scale‑up capabilities are positioned to capture a larger share of this growing market.

📈 Key Trends Shaping the Market:

• Rapid growth of peptide‑based therapeutics and the expanding drug pipeline.
• Adoption of advanced peptide synthesis technologies, including automated solid‑phase synthesizers and flow‑chemistry platforms.
• Demand for orthogonal protection strategies, driving the need for dual‑protected building blocks.
• Increasing outsourcing of specialty chemical synthesis to fine‑chemical manufacturers.
• Digitalization of chemical procurement, improving market accessibility for niche intermediates.